Abstract
Subcutaneous (SC) formulations of daratumumab replace the previous need for intravenous infusion, potentially enabling treatment to be provided at alternative sites of care. This research aims to evaluate if daratumumab SC injection for multiple myeloma in the home care setting can provide value to patients and hospitals in terms of time spent on treatment and associated costs, versus receiving treatment in the Spanish hospital setting.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
